Clear cell hepatocellular carcinoma: Gd-EOB-DTPA-enhanced MR imaging features and prognosis

被引:1
作者
Song, Mingyue [1 ,2 ]
Tao, Yuhao [1 ,2 ]
He, Kuang [3 ]
Du, Mingzhan [3 ]
Guo, Lingchuan [3 ]
Hu, Chunhong [2 ]
Zhang, Weiguo [1 ,2 ]
机构
[1] Soochow Univ, Dept Radiol, Affiliated Hosp 4, Changzhou 215028, Jiangsu, Peoples R China
[2] Soochow Univ, Dept Radiol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[3] Soochow Univ, Dept Pathol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
关键词
Hepatocellular carcinoma; Magnetic Resonance Imaging; Gadolinium ethoxybenzyl DTPA; Prognosis; SIGNAL INTENSITY; HEPATIC-UPTAKE; LIVER; SUBTYPES; CT;
D O I
10.1007/s00261-024-04263-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To investigate imaging findings on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) and prognosis of clear cell hepatocellular carcinoma (CCHCC) comparing with non-otherwise specified hepatocellular carcinoma (NOS-HCC). Methods The clinical, pathological and MR imaging features of 42 patients with CCHCC and 84 age-matched patients with NOS-HCC were retrospectively analyzed from January 2015 to October 2021. Univariate and multivariate logistic regression and Cox regression analyses were performed to identify independent diagnostic and prognostic factors for CCHCC. Disease-free survival (DFS) and overall survival (OS) were determined by Kaplan-Meier analysis. Results CCHCC showed fat content more frequently (P < 0.001) and relatively higher Edmondson tumor grade (P = 0.001) compared with NOS-HCC. The lesion-to-muscle ratio (LMR) and lesion-to-liver ratio (LLR) of CCHCC on pre-enhancement T1-weighted imaging (pre-T1WI) (P = 0.001, P = 0.003) and hepatobiliary phase (HBP) (P = 0.007, P = 0.048) were significantly higher than those of NOS-HCC. The area under the curve (AUC) for fat content, LLR on pre-T1WI and their combination with better diagnostic performance in predicting CCHCC were 0.678, 0.666, and 0.750, respectively. There was no statistically significant difference in clinical outcomes between CCHCC and NOS-HCC. Multivariate Cox analysis confirmed that tumor size > 2 cm and enhancing capsule were independent prognostic factors for DFS and OS among CCHCC patients. Conclusion Fat content and adjusted lesion signal intensity on pre-T1WI and HBP could be used to differentiate CCHCC from NOS-HCC. CCHCC had similar prognosis with NOS-HCC.
引用
收藏
页码:2116 / 2124
页数:9
相关论文
共 42 条
[1]   Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5th edition of the World Health Organization classification [J].
Auer, Timo A. ;
Halskov, Sebastian ;
Fehrenbach, Uli ;
Nevermann, Nora F. ;
Pelzer, Uwe ;
Mohr, Raphael ;
Hamm, Bernd ;
Schoening, Wenzel ;
Horst, David ;
Ihlow, Jana ;
Geisel, Dominik .
EUROPEAN RADIOLOGY, 2023, 33 (10) :6902-6915
[2]   Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells [J].
Bannasch, Peter ;
Ribback, Silvia ;
Su, Qin ;
Mayer, Doris .
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (06) :570-594
[3]  
BUCHANAN TF, 1974, AM J CLIN PATHOL, V61, P529
[4]   Hepatocellular Carcinoma Variants: Radiologic-Pathologic Correlation [J].
Chung, Yong Eun ;
Park, Mi-Suk ;
Park, Young Nyun ;
Lee, Hye-Jeong ;
Seok, Jae Yeon ;
Yu, Jeong-Sik ;
Kim, Myeong-Jin .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (01) :W7-W13
[5]   Small hepatocellular carcinoma: Relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma [J].
Ebara, M ;
Fukuda, H ;
Kojima, Y ;
Morimoto, N ;
Yoshikawa, M ;
Sugiura, N ;
Satoh, T ;
Kondo, F ;
Yukawa, M ;
Matsumoto, T ;
Saisho, H .
RADIOLOGY, 1999, 210 (01) :81-88
[6]   Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis [J].
Enomoto, Shotaro ;
Tamai, Hideyuki ;
Shingaki, Naoki ;
Mori, Yoshiyuki ;
Moribata, Kosaku ;
Shiraki, Tatsuya ;
Deguchi, Hisanobu ;
Ueda, Kazuki ;
Inoue, Izumi ;
Maekita, Takao ;
Iguchi, Mikitaka ;
Yanaoka, Kimihiko ;
Oka, Masashi ;
Ichinose, Masao .
HEPATOLOGY INTERNATIONAL, 2011, 5 (02) :730-737
[7]   EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018) [J].
Galle, Peter R. ;
Forner, Alejandro ;
Llovet, Josep M. ;
Mazzaferro, Vincenzo ;
Piscaglia, Fabio ;
Raoul, Jean-Luc ;
Schirmacher, Peter ;
Vilgrain, Valerie .
JOURNAL OF HEPATOLOGY, 2019, 70 (04) :817-817
[8]   Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade [J].
Haimerl, Michael ;
Utpatel, Kirsten ;
Goetz, Andrea ;
Zeman, Florian ;
Fellner, Claudia ;
Nickel, Dominik ;
Luerken, Lukas ;
Brennfleck, Frank ;
Stroszczynski, Christian ;
Scheiter, Alexander ;
Verloh, Niklas .
SCIENTIFIC REPORTS, 2021, 11 (01)
[9]   AASLD guidelines for the treatment of hepatocellular carcinoma [J].
Heimbach, Julie K. ;
Kulik, Laura M. ;
Finn, Richard S. ;
Sirlin, Claude B. ;
Abecassis, Michael M. ;
Roberts, Lewis R. ;
Zhu, Andrew X. ;
Murad, M. Hassan ;
Marrero, Jorge A. .
HEPATOLOGY, 2018, 67 (01) :358-380
[10]   Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation [J].
Huang, Kun ;
Dong, Zhi ;
Cai, Huasong ;
Huang, Mengqi ;
Peng, Zhenpeng ;
Xu, Ling ;
Jia, Yingmei ;
Song, Chenyu ;
Li, Zi-Ping ;
Feng, Shi-Ting .
BMC CANCER, 2019, 19 (1)